Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News | Stock Analysis
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Breakeven On The Horizon For Puma Biotechnology, Inc. (NASDAQ:PBYI) | Nasdaq
Puma investors look for second lightning strike | Evaluate
Vir Biotech IPO: What You Need To Know
Reverse Mergers Losing Out to Lower-Cost Offerings - TheStreet
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
Puma Biotechnology, Inc. | LinkedIn
Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer - Puma Biotechnology (NASDAQ:PBYI) - Benzinga
Puma Biotechnology Inc. (NYSE: PBYI) shareholders vote against PPD founder Fred Eshelman - Triangle Business Journal
Why Puma Biotechnology Is Soaring Today | Nasdaq
Alan H. Auerbach - Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile
Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News | Stock Analysis
